Cited by 7,449Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction ResearchCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

Open access

Shepherd, James, Cobbe, Stuart M., Ford, Ian, Isles, Christopher G., Lorimer, A. Ross, Macfarlane, Peter W., McKillop, James H., Packard, Christopher J.·1995·New England Journal of Medicine

DOI 10.1056/nejm199511163332001

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Lowering the blood cholesterol level may reduce the risk of coronary heart disease. This double-blind study was designed to determine whether the administration of pravastatin to men with hypercholesterolemia and no history of myocardial infarction reduced the combined incidence of nonfatal myocardial infarction and death from coronary heart disease. METHODS: We randomly assigned 6595 men, 45 to 64 years of age, with a mean (+/- SD) plasma cholesterol level of 272 +/- 23 mg per deciliter (7.0 +/- 0.6 mmol per liter) to receive pravastatin (40 mg each evening) or placebo. The average follow-up period was 4.9 years. Medical records, electrocardiographic recordings, and the national death registry were used to determine the clinical end points. RESULTS: Pravastatin lowered plasma cholesterol levels by 20 percent and low-density-lipoprotein cholesterol levels by 26 percent, whereas there was no change with placebo. There were 248 definite coronary events (specified as nonfatal myocardial infarction or death from coronary heart disease) in the placebo group, and 174 in the pravastatin group (relative reduction in risk with pravastatin, 31 percent; 95 percent confidence interval, 17 to 43 percent; P < 0.001). There were similar reductions in the risk of definite nonfatal myocardial infarctions (31 percent reduction, P < 0.001), death from coronary heart disease (definite cases alone: 28 percent reduction, P = 0.13; definite plus suspected cases: 33 percent reduction, P = 0.042), and death from all cardiovascular causes (32 percent reduction, P = 0.033). There was no excess of deaths from noncardiovascular causes in the pravastatin group. We observed a 22 percent reduction in the risk of death from any cause in the pravastatin group (95 percent confidence interval, 0 to 40 percent; P = 0.051). CONCLUSIONS: Treatment with pravastatin significantly reduced the incidence of myocardial infarction and death from cardiovascular causes without adversely affecting the risk of death from noncardiovascular causes in men with moderate hypercholesterolemia and no history of myocardial infarction.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199511163332001

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease
(1984) · JAMA · doi:10.1001/jama.1984.03340270029025 · Cited by 2,747
MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.
(1985) · BMJ · doi:10.1136/bmj.291.6488.97 · Cited by 1,491
Modelling Survival Data in Medical Research
Collett, D. (1994) · Springer eBooks · doi:10.1007/978-1-4899-3115-3 · Cited by 1,064
A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.
Oliver, M., Heady, J., Morris, J. N., Cooper, J., Geizerova, H., Gyárfás, I., Green, K., Strasser, T., Macfie, W. G., Scott, E., et al. (1978) · Heart · doi:10.1136/hrt.40.10.1069 · Cited by 1,047
Modelling Survival Data in Medical Research.
McLachlan, G. J., & Collett, D. (1994) · Biometrics · doi:10.2307/2533471 · Cited by 1,023
Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
Jukema, J., Bruschke, A. V., van Boven, A. J., Reiber, J., Bal, E., Zwinderman, A., Jansen, H., Boerma, G., van Rappard, F. M., & Kong, L. I. (1995) · Circulation · doi:10.1161/01.cir.91.10.2528 · Cited by 911
Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
Furberg, C. D., Adams, H. P., Applegate, W. B., Byington, R. P., Espeland, M. A., Hartwell, T., Hunninghake, D. B., Lefkowitz, D. S., Probstfield, J. L., & Riley, W. A. (1994) · Circulation · doi:10.1161/01.cir.90.4.1679 · Cited by 865

Show all 26 references

Research works printed but not linked: 4

10.1001/jama.251.3.351 · DOI · Paper page
1994, Lancet, 344, 1383
1992, Nutr Metab Cardiovasc Dis, 2, 113
Macfarlane PW, 1990, Eur Heart J, 11, 411

Sorted by citations

Items 901–1,000 of 1,060

Joint British recommendations on prevention of coronary heart disease in clinical practice
Cheesman, M., Leech, G. J., Chambers, J. B., Monaghan, M. J., & Nihoyannopoulos, P. (1998) · Heart · doi:10.1136/hrt.80.2008.1s · Cited by 176
Serial Metabolic Measurements and Conversion to Type 2 Diabetes in the West of Scotland Coronary Prevention Study
Sattar, N., McConnachie, A., Ford, I., Gaw, A., Cleland, S. J., Forouhi, N. G., McFarlane, P., Shepherd, J., Cobbe, S., & Packard, C. (2007) · Diabetes · doi:10.2337/db06-1256 · Cited by 127
Self-citation
A new method for CHD prediction and prevention based on regional risk scores and randomized clinical trials; PRECARD(R) and the Copenhagen Risk Score
Thomsen, T. F., Davidsen, M., Ibsen, H., Jorgensen, T., Jensen, G., & Borch-Johnsen, K. (2001) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/174182670100800508 · Cited by 127
Muscular Side Effects of Statins
Sinzinger, H. F., Wolfram, R. M., & Peskar, B. A. (2002) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200208000-00001 · Cited by 127
Anti-inflammatory mechanism of simvastatin in mouse allergic asthma model
Kim, D. Y., Ryu, S. Y., Lim, J. E., Lee, Y. S., & Ro, J. Y. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.11.027 · Cited by 128
Prevention Conference V
Grundy, S. M., Bazzarre, T. L., Cleeman, J. I., D’Agostino, R. B., Hill, M. N., Miller, N. H., Kannel, W. B., Krauss, R. M., Krumholz, H. M., Lauer, R. M., et al. (2000) · Circulation · doi:10.1161/01.cir.101.1.e3 · Cited by 127
Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-analysis
Kang, S., Wu, Y., & Li, X. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.08.005 · Cited by 126
Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein
Ridker, P. M., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Khurmi, N. S., Köenig, W., Libby, P., Lorenzatti, A. J., Nordestgaard, B. G., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.09.072 · Cited by 125
Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis
de Maat, M. P. M., Jukema, J. W., Ye, S., Zwinderman, A. H., Moghaddam, P. H., Beekman, M., Kastelein, J. J. P., Boven, A. J. V., Bruschke, A. V. G., Humphries, S. E., et al. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)01073-x · Cited by 126
Using Pravastatin to Improve the Vascular Reactivity in a Mouse Model of Soluble Fms-Like Tyrosine Kinase-1–Induced Preeclampsia
Costantine, M. M., Tamayo, E. H., Lu, F., Bytautiene, E., Longo, M., Hankins, G. D. V., & Saade, G. R. (2010) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e3181e10ebd · Cited by 126
Fluvastatin Prevents Cardiac Death and Myocardial Infarction in Renal Transplant Recipients: Post-Hoc Subgroup Analyses of the ALERT Study
Jardine, A. G., Holdaas, H., Fellström, B., Cole, E., Nyberg, G., Grönhagen‐Riska, C., Madsen, S., Neumayer, H., Maes, B., Ambühl, P. M., et al. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00445.x · Cited by 125
Encounter Frequency and Serum Glucose Level, Blood Pressure, and Cholesterol Level Control in Patients With Diabetes Mellitus
Morrison, F. J. R. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.400 · Cited by 125
Controversial role of plant sterol esters in the management of hypercholesterolaemia
Weingärtner, O., Böhm, M., & Laufs, U. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn580 · Cited by 125
Lipoprotein abnormalities in South Asians and its association with cardiovascular disease: Current state and future directions
Bilen, O., Kamal, A. K., & Virani, S. S. (2016) · World Journal of Cardiology · doi:10.4330/wjc.v8.i3.247 · Cited by 132
Interleukin-6, Fibrin D-Dimer, and Coagulation Factors VII and XIIa in Prediction of Coronary Heart Disease
Lowe, G. D. O., Rumley, A., McMahon, A. D., Ford, I., O’Reilly, D. S. J., & Packard, C. J. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000135995.39488.6c · Cited by 125
Strategies to achieve coronary arterial plaque stabilization
Rabbani, R. (1999) · Cardiovascular Research · doi:10.1016/s0008-6363(98)00279-x · Cited by 125
Use of statins in CNS disorders
Cucchiara, B. L., & Kasner, S. E. (2001) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(01)00529-9 · Cited by 125
Serum lipid levels in an Iranian adults population: Tehran lipid and glucose study
Azizi, F., Rahmani, M., Ghanbarian, A., Emami, H., Salehi, P., Mirmiran, P., & Sarbazi, N. (2003) · European Journal of Epidemiology · doi:10.1023/a:1023606524944 · Cited by 124
Effect of statin therapy on restenosis after coronary stent implantation
Walter, D. H., Schächinger, V., Elsner, M., Mach, S., Auch–Schwelk, W., & Zeiher, A. M. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00910-8 · Cited by 120
Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: a 1-year longitudinal study
Montagnani, A., Gonnelli, S., Cepollaro, C., Pacini, S., Campagna, M. S., Franci, M. B., Lucani, B., & Gennari, C. (2003) · Bone · doi:10.1016/s8756-3282(03)00034-6 · Cited by 120
Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease
Bickel, C., Rupprecht, H. J., Blankenberg, S., Espinola–Klein, C., Schlitt, A., Rippin, G., Hafner, G., Treude, R., Othman, H., Hofmann, K.-P., et al. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02236-1 · Cited by 123
Fluvastatin
Plosker, G. L., & Wagstaff, A. J. (1996) · Drugs · doi:10.2165/00003495-199651030-00011 · Cited by 123
Cholesterol Lowering in the Elderly Population
Grundy, S. M. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.15.1670 · Cited by 121
Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview
Suh, S. H., & Kim, S. W. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0067 · Cited by 138
Clinical Pharmacokinetics of Cerivastatin
ck, W. M. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200039020-00002 · Cited by 122
Expression of adhesion molecules by Lp(a): a potential novel mechanism for its atherogenicity
Allen, S. P., Khan, S., Tam, S., Koschinsky, M. L., Taylor, P., & Yacoub, M. H. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.15.1765 · Cited by 121
Biologic markers as predictors of cardiovascular disease
Frishman, W. H. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00184-3 · Cited by 120
Effect of statin therapy on restenosis after coronary stent implantation
Malik, I. S., Khan, M., & Beatt, K. J. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01156-5 · Cited by 121
Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells
Hernández-Presa, M. Á., Martı́n-Ventura, J. L., Ortego, M., Gómez‐Hernández, A., Tuñón, J., Hernández-Vargas, P., Blanco‐Colio, L. M., Mas, S., Aparicio, C., Ortega, L. M., et al. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00547-0 · Cited by 122
Therapy Insight: potential of statins for cancer chemoprevention and therapy
Katz, M. S. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0097 · Cited by 122
Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy
Li, C., Yang, C. W., Park, J. H., Lim, S. W., Sun, B., Jung, J., Kim, S. B., Kim, Y., Kim, J., & Bang, B. K. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00428.2002 · Cited by 123
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Writing Committee Members, Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001423 · Cited by 122
LDL-C: lower is better for longer—even at low risk
Penson, P. E., Pirro, M., & Banach, M. (2020) · BMC Medicine · doi:10.1186/s12916-020-01792-7 · Cited by 121
Establishing the Cost-Effectiveness of New Pharmaceuticals under Conditions of Uncertainty—When Is There Sufficient Evidence?
Sculpher, M., & Claxton, K. (2005) · Value in Health · doi:10.1111/j.1524-4733.2005.00033.x · Cited by 123
Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)
Packard, C. J., Ford, I., Robertson, M., Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L. E. M., Buckley, B. M., Cobbe, S. M., Gaw, A., et al. (2005) · Circulation · doi:10.1161/circulationaha.104.526848 · Cited by 121
Effects of yoghurt enriched with plant sterols on serum lipids in patients with moderate hypercholesterolaemia
Volpe, R. J., Niittynen, L., Korpela, R., Sirtori, C. R., Bucci, A., Fraone, N., & Pazzucconi, F. (2001) · British Journal Of Nutrition · doi:10.1079/bjn2001395 · Cited by 120
Effects of Cigarette Smoking on the Angiographic Evolution of Coronary Atherosclerosis
Waters, D. D., Lespérance, J., Gladstone, P. J., Boccuzzi, S. J., Cook, T. J., Hudgin, R. L., Krip, G., & Higginson, L. (1996) · Circulation · doi:10.1161/01.cir.94.4.614 · Cited by 120
The cardiovascular dysmetabolic syndrome
Fagan, T. C., & DEEDWANIA, P. C. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00216-2 · Cited by 121
Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease
Seljeflot, I., Tonstad, S., Hjermann, I., & Arnesen, H. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00696-7 · Cited by 117
People, places and coronary heart disease risk factors: A multilevel analysis of the Scottish heart health study archive
Hart, C., Ecob, R., & Smith, G. D. (1997) · Social Science & Medicine · doi:10.1016/s0277-9536(96)00431-5 · Cited by 120
Reduction of Serum Ubiquinol-10 and Ubiquinone-10 Levels by Atorvastatin in Hypercholesterolemic Patients
Mabuchi, H., Higashikata, T., Kawashiri, M., Katsuda, S., Mizuno, M., Nohara, A., Inazu, A., Koizumi, J., & Kobayashi, J. (2005) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.12.111 · Cited by 119
Increased Levels of 25 Hydroxyvitamin D and 1,25-Dihydroxyvitamin D After Rosuvastatin Treatment: A Novel Pleiotropic Effect of Statins?
Yavuz, B., Ertuğrul, D. T., Cil, H., Ata, N., Akın, K. O., Yalçın, A. A., Küçükazman, M., Dal, K., Hokkaomeroglu, M. S., Yavuz, B. B., et al. (2009) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-009-6181-8 · Cited by 120
Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy
Moyle, G. J., Lloyd, M., Reynolds, B., Baldwin, C., Mandalia, S., & Gazzard, B. (2001) · AIDS · doi:10.1097/00002030-200108170-00007 · Cited by 119
Statin Use and Risk of Colorectal Cancer
Coogan, P. F., Smith, J., & Rosenberg, L. A. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk003 · Cited by 119
A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis
Patel, T. N., Shishehbor, M. H., & Bhatt, D. L. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehl445 · Cited by 119
Simvastatin decreases aldehyde production derived from lipoprotein oxidation
Girona, J., Ville, A. E. L., Solà, R., Plana, N., & Masana, L. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)01071-6 · Cited by 119
Treatment of adults with Familial Hypercholesterolemia and evidence for treatment: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia
Robinson, J. G., & Goldberg, A. C. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.03.451 · Cited by 120
The effects of old, new and emerging medicines on metabolic aberrations in PCOS
Bargiota, Α., & Diamanti‐Kandarakis, E. (2012) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018812437355 · Cited by 120
A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease
Scott, R. A., Freitag, D. F., Li, L., Chu, A. Y., Surendran, P., Young, R., Grarup, N., Stančáková, A., Chen, Y., Varga, T. V., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad3744 · Cited by 115
Ubiquinone: cholesterol's reclusive cousin
Hargreaves, I. P. (2003) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/000456303321610493 · Cited by 118
Comparison of the risk factors for coronary artery spasm with those for organic stenosis in a Japanese population: role of cigarette smoking
Takaoka, K., Yoshimura, M., Ogawa, H., Kugiyama, K., Nakayama, M., Shimasaki, Y., Mizuno, Y., Sakamoto, T., & Yasue, H. (2000) · International Journal of Cardiology · doi:10.1016/s0167-5273(99)00172-2 · Cited by 118
A Comprehensive Description of Muscle Symptoms Associated with Lipid-Lowering Drugs
Franc, S., Dejager, S., Bruckert, É., Chauvenet, M., Giral, P., & Turpin, G. (2003) · Cardiovascular Drugs and Therapy · doi:10.1023/b:card.0000015861.26111.ab · Cited by 117
Communicating the risk reduction achieved by cholesterol reducing drugs
Skolbekken, J. (1998) · BMJ · doi:10.1136/bmj.316.7149.1956 · Cited by 118
Statins: panacea for sepsis?
Terblanche, M., Almog, Y., Rosenson, R. S., Smith, T. S., & Hackam, D. G. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70439-x · Cited by 118
ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death—Executive Summary
Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., CHAITMAN, B. R., FROMER, M. A., Gregoratos, G., Klein, G. J., Moss, A. J., Myerburg, R. J., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.178104 · Cited by 119
Aggressive Cholesterol Lowering Delays Saphenous Vein Graft Atherosclerosis in Women, the Elderly, and Patients With Associated Risk Factors
CAMPEAU, L. A., Hunninghake, D. B., Knatterud, G. L., White, C. W., DOMANSKI, M. J., Forman, S. A., Forrester, J. S., Geller, N. L., Gobel, F. L., Herd, J. A., et al. (1999) · Circulation · doi:10.1161/01.cir.99.25.3241 · Cited by 117
A simple computer program for guiding management of cardiovascular risk factors and prescribing
Hingorani, A. D., & Vallance, P. J. (1999) · BMJ · doi:10.1136/bmj.318.7176.101 · Cited by 118
Baseline Risk Factors and their Association With Outcome in the West of Scotland Coronary Prevention Study
Cobbe, S. M. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00863-6 · Cited by 118
Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin
Kosoglou, T., Meyer, I., Veltri, E. P., Statkevich, P., Yang, B., Zhu, Y., Mellars, L., Maxwell, S. E., Patrick, J. E., Cutler, D. L., et al. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01633.x · Cited by 117
Understanding the potential role of statins in pneumonia and sepsis*
Yende, S. P., Milbrandt, E. B., Kellum, J. A., et al. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e31821b8290 · Cited by 117
Effects of Evolocumab (AMG 145), a Monoclonal Antibody to PCSK9, in Hypercholesterolemic, Statin-Treated Japanese Patients at High Cardiovascular Risk
Hirayama, A., Honarpour, N., Yoshida, M., Yamashita, S., Huang, F., Wasserman, S. M., & Teramoto, T. (2014) · Circulation Journal · doi:10.1253/circj.cj-14-0130 · Cited by 117
Interactions Between Enhanced Polygenic Risk Scores and Lifestyle for Cardiovascular Disease, Diabetes, and Lipid Levels
Ye, Y., Chen, X. D., Han, J. J., Jiang, W., Natarajan, P., & Zhao, H. (2021) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.120.003128 · Cited by 119
Practical applications in stress echocardiography
Yao, S., Qureshi, E. A., Sherrid, M. V., & Chaudhry, F. A. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00923-9 · Cited by 118
Use of statins in the secondary prevention of coronary heart disease: is treatment equitable?
Reid, F., Cook, D. G., & Whincup, P. H. (2002) · Heart · doi:10.1136/heart.88.1.15 · Cited by 117
Secretory phospholipase A2 of group IIA: Is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases?
Menschikowski, M., Hagelgans, A., & Siegert, G. (2005) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2005.10.005 · Cited by 117
Simvastatin does not exhibit therapeutic anti-inflammatory effects in asthma
Menzies, D., Nair, A., Meldrum, K. T., Fleming, D., Barnes, M. L., & Lipworth, B. J. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.10.014 · Cited by 117
Statin therapy improves cardiovascular outcome of patients with peripheral artery disease
Schillinger, M. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.02.012 · Cited by 117
Impact of Concurrent Medication Use on Statin Adherence and Refill Persistence
Grant, R. W., O'Leary, K. M., Weilburg, J. B., Singer, D. E., & Meigs, J. B. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.21.2343 · Cited by 117
Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS)
Yokoyama, M., & Origasa, H. (2003) · American Heart Journal · doi:10.1016/s0002-8703(03)00367-3 · Cited by 117
Relation of Coronary Calcium Score by Electron Beam Computed Tomography to Arteriographic Findings in Asymptomatic and Symptomatic Adults
Guerci, A. D., Spadaro, L. A., Popma, J. J., Goodman, K. J., Brundage, B. H., Budoff, M. J., Lerner, G., & Vizza, R. F. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00698-4 · Cited by 117
Effect of combining psyllium fiber with simvastatin in lowering cholesterol
Moreyra, A. E. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.10.1161 · Cited by 117
Cholesterol and Arterial Distensibility in the First Decade of Life
Leeson, C. P. M., Whincup, P. H., Cook, D. G., Mullen, M., Donald, A. E., Seymour, C. A., & Deanfield, J. E. (2000) · Circulation · doi:10.1161/01.cir.101.13.1533 · Cited by 118
Similar Effects of Atorvastatin, Simvastatin and Pravastatin on Thrombogenic and Inflammatory Parameters in Patients with Hypercholesterolemia
Joukhadar, C., Klein, N., Prinz, M., Schrolnberger, C., Vukovich, T., Wolzt, M., Dorner, G. T., & Schmetterer, L. F. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1612902 · Cited by 116
Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease
Schaefer, J. R. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00053-2 · Cited by 114
Dietary fat and adult diseases and the implications for childhood nutrition: an epidemiologic approach
Law, M. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.5.1291s · Cited by 115
Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy
Benner, J. S., Tierce, J. C., Ballantyne, C. M., Prasad, C., Bullano, M. F., Willey, V. J., Erbey, J., & Sugano, D. S. (2004) · PharmacoEconomics · doi:10.2165/00019053-200422003-00003 · Cited by 115
Atherogenecity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux
Nielsen, L. B. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00064-7 · Cited by 115
Impact of Pharmacy Counseling on Compliance and Effectiveness of Combination Lipid‐Lowering Therapy in Patients Undergoing Coronary Artery Revascularization: A Randomized, Controlled Trial
Faulkner, M. A., Wadibia, E. C., Lucas, B. D., & Hilleman, D. E. (2000) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.5.410.35048 · Cited by 115
Ppars, metabolic disease and atherosclerosis
Fruchart, J., Staels, B., & Duriez, P. (2001) · Pharmacological Research · doi:10.1006/phrs.2001.0871 · Cited by 115
HMG-CoA reductase inhibitors (statins)
Hess, D. C., Demchuk, A. M., Brass, L. M., & Yatsu, F. M. (2000) · Neurology · doi:10.1212/wnl.54.4.790 · Cited by 112
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Navaneethan, S. D., Pansini, F., Perkovic, V., Manno, C., Pellegrini, F., Johnson, D. W., Craig, J. C., & Strippoli, G. F. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007784 · Cited by 117
Statins and the risk of colorectal cancer: An updated systematic review and meta-analysis of 40 studies
Lytras, T. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i7.1858 · Cited by 119
Screening, prevention, counseling, and treatment for the complications of type II diabetes mellitus
Vijan, S. S., Stevens, D. L., Herman, W. H., Funnell, M. M., & Standiford, C. J. (1997) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.1997.07111.x · Cited by 114
Lipid-lowering therapy with statins reduces microparticle shedding from endothelium, platelets and inflammatory cells
Suades, R., Padró, T., Rodrigo Alonso, K., Mata, P., & Badimón, L. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-03-0238 · Cited by 115
Statins, Low-Density Lipoprotein Cholesterol, and Risk of Cancer
Alsheikh-Ali, A. A. A., Trikalinos, T. A., Kent, D. M., & Karas, R. H. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.06.037 · Cited by 113
A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study
Freeman, D. J. (2003) · European Heart Journal · doi:10.1016/j.ehj.2003.07.001 · Cited by 114
Evidence of Lifestyle Modification in the Management of Hypercholesterolemia
Mannu, G., Zaman, M., Gupta, A., Rehman, H. U., & Myint, P. K. (2013) · Current Cardiology Reviews · doi:10.2174/157340313805076313 · Cited by 121
Low High-Density Lipoprotein Cholesterol as a Risk Factor in Coronary Heart Disease
Gotto, A. M. (2001) · Circulation · doi:10.1161/01.cir.103.17.2213 · Cited by 113
Use and Monitoring of "Statin" Lipid-Lowering Drugs Compared With Guidelines
Abookire, S. A., Karson, A. S., Fiskio, J. M., & Bates, D. W. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.1.53 · Cited by 114
Common Hepatic Lipase Gene Promoter Variant Determines Clinical Response to Intensive Lipid-Lowering Treatment
Zambon, A., Deeb, S. S., Brown, B. G., Hokanson, J. E., & Brunzell, J. D. (2001) · Circulation · doi:10.1161/01.cir.103.6.792 · Cited by 114
Lipid Management to Reduce Cardiovascular Risk: A New Strategy Is Required
Superko, H. R., & King, S. B. (2008) · Circulation · doi:10.1161/circulationaha.106.667428 · Cited by 112
Simvastatin Acutely Reduces Myocardial Reperfusion Injury In Vivo by Activating the Phosphatidylinositide 3-Kinase/Akt Pathway
Wolfrum, S., Dendorfer, A., Schütt, M., Weidtmann, B., Heep, A., Tempel, K., Klein, H. H., Dominiak, P., & Richardt, G. (2004) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000137162.14735.30 · Cited by 113
Micronised Fenofibrate
Keating, G. M., & Ormrod, D. J. (2002) · Drugs · doi:10.2165/00003495-200262130-00013 · Cited by 114
Family physicians' use of medical abstracts to guide decision making: style or substance?
Barry, H. C., Ebell, M. H., Shaughnessy, A. F., Slawson, D. C., & Nietzke, F. (2001) · PubMed · Cited by 113
Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice
Frolkis, J. P., Pearce, G. L., Nambi, V., Minor, S., & Sprecher, D. L. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01303-7 · Cited by 113
Cardiovascular Morbidity Associated with Nonadherence to Statin Therapy
Blackburn, D. F., Dobson, R. T., Blackburn, J. L., & Wilson, T. W. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2005.25.8.1035 · Cited by 112
Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia–reperfusion injury in rat hearts
Napoli, P. D., Taccardi, A. A., Grilli, A., Delutiis, M. A., Barsotti, A., Felaco, M., & DeCaterina, R. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.02.008 · Cited by 111
Association of Serum Lipids and Coronary Heart Disease in Contemporary Observational Studies
Colantonio, L. D., Bittner, V., Reynolds, K., Levitan, E. B., Rosenson, R. S., Banach, M., Kent, S. T., Derose, S. F., Zhou, H., Safford, M. M., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.011646 · Cited by 105
Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study
McConnachie, A., Walker, A., Robertson, M., Marchbank, L., Peacock, J., Packard, C. J., Cobbe, S. M., & Ford, I. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht232 · Cited by 104
Self-citation
Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature
Yu, M., Liang, C., Kong, Q., Wang, Y., & Li, M. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-019-1182-5 · Cited by 107

Authors: Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J.
Affiliations: Glasgow Royal Infirmary (GB)
University of Glasgow (GB)
NHS Dumfries and Galloway (GB)
ORCID: Ford, Ian
Macfarlane, Peter W.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1995-11-16
Volume: 333
Issue: 20
Pages: 1301-1308
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199511163332001
OpenAlex: W2155598961
Semantic Scholar: 1aa5f64bbe1d0c4c74fc3de7c89ac2dffb48630a
Cited by: 7,449
References: 26
Citations by year: 2026: 31 · 2025: 33 · 2024: 56 · 2023: 54 · 2022: 66 · 2021: 72 · 2020: 95 · 2019: 90 · 2018: 108 · 2017: 121 · 2016: 157 · 2015: 137 · 2014: 177 · 2013: 215 · 2012: 197
FWCI: 344.87
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Bristol-Myers Squibb
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: pravastatin, hypercholesterolemia, coronary heart disease prevention, statins, LDL cholesterol lowering, nonfatal myocardial infarction, cardiovascular mortality, men, cholesterol-lowering therapy
MeSH terms: Anticholesteremic Agents, Cholesterol, Coronary Disease, Double-Blind Method, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Neoplasms, Risk, Incidence, Survival Analysis, Pravastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks